NOVTU | Ticker Profile - Titan Protect

NOVTU

Novanta Inc.

Technology · Scientific & Technical Instruments · NMS

$66.07

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

LIMITED

Data Confidence: 42.9%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

N/A

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

+10.4%

Year-over-year revenue change

Profit Margin

5.3%

How much profit the company keeps from each dollar of revenue

ROE

5.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Novanta Inc.

Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally. The company operates Automation Enabling Technologies and Medical Solutions segments. The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles. This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications. The Medical Solutions segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; imaging, identification and RFID solutions; advanced motion control solutions; and light engines, and integrated operating room technologies. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was incorporated in 1968 and is based in Bedford, Massachusetts.

https://www.novanta.com

Country: United States Employees: 3,000 Industry: Scientific & Technical Instruments

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.925

Excellent risk-adjusted returns

Kelly Fraction

0.0889

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

4.877

Returns exceed worst-case losses — strong risk profile

Annual Return

93.5%

Historical annualised return based on price data

Max Drawdown

-19.2%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.62

Significantly more volatile than the market

52W High

$70.04

6% below the year high

52W Low

$47.57

39% above the year low

Avg Volume

67,836

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$N/A

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

22.22

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.56

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.55

Like current ratio but excludes inventory — stricter test

Gross Margin

44.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

11.7%

Profit from core operations before interest and tax

Free Cash Flow

$87M

Positive — the business generates more cash than it spends

Revenue (TTM)

$1.0B

Total revenue over the last 12 months

Net Income

$54M

Profitable — the bottom line is positive

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go